• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

带有双齿PhPCHCHSPh-κ,κ配体的(五甲基环戊二烯基)氯铱(III)配合物

(Pentamethylcyclopentadienyl)chloridoiridium(III) Complex Bearing Bidentate PhPCHCHSPh-κ,κ Ligand.

作者信息

Ludwig Gerd, Ranđelović Ivan, Dimić Dušan, Komazec Teodora, Maksimović-Ivanić Danijela, Mijatović Sanja, Rüffer Tobias, Kaluđerović Goran N

机构信息

Institute of Chemistry, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Straße 2, D-06120 Halle, Germany.

Department of Immunology, Institute for Biological Research "Sinisa Stankovic"-National Institute of the Republic of Serbia, University of Belgrade, Bulevar Despota Stefana 142, 11108 Belgrade, Serbia.

出版信息

Biomolecules. 2024 Mar 30;14(4):420. doi: 10.3390/biom14040420.

DOI:10.3390/biom14040420
PMID:38672437
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11048224/
Abstract

The (pentamethylcyclopentadienyl)chloridoiridium(III) complex bearing a κ,κ-bonded PhPCHCHSPh ligand ([Ir(η-CMe)Cl(PhP(CH)SPh-κκ)]PF, ()] was synthesized and characterized. Multinuclear (H, C and P) NMR spectroscopy was employed for the determination of the structure. Moreover, SC-XRD confirmed the proposed structure belongs to the "piano stool" type. The Hirshfeld surface analysis outlined the most important intermolecular interactions in the structure. The crystallographic structure was optimized at the B3LYP-D3BJ/6-311++G(d,p)(H,C,P,S,Cl)/LanL2DZ(Ir) level of theory. The applicability of this level was verified through a comparison of experimental and theoretical bond lengths and angles, and H and C NMR chemical shifts. The Natural Bond Orbital theory was used to identify and quantify the intramolecular stabilization interactions, especially those between donor atoms and Ir(III) ions. Complex was tested on antitumor activity against five human tumor cell lines: MCF-7 breast adenocarcinoma, SW480 colon adenocarcinoma, 518A2 melanoma, 8505C human thyroid carcinoma and A253 submandibular carcinoma. Complex showed superior antitumor activity against cisplatin-resistant MCF-7, SW480 and 8505C cell lines. The mechanism of tumoricidal action on 8505C cells indicates the involvement of caspase-induced apoptosis, accompanied by a considerable reduction in ROS/RNS and proliferation potential of treated cells.

摘要

合成并表征了带有κ,κ-键合的PhPCHCHSPh配体([Ir(η-CMe)Cl(PhP(CH)SPh-κκ)]PF,())的(五甲基环戊二烯基)氯铱(III)配合物。采用多核(H、C和P)核磁共振光谱法测定结构。此外,单晶X射线衍射证实所提出的结构属于“钢琴凳”类型。 Hirshfeld表面分析概述了该结构中最重要的分子间相互作用。在B3LYP-D3BJ/6-311++G(d,p)(H,C,P,S,Cl)/LanL2DZ(Ir)理论水平上对晶体结构进行了优化。通过比较实验和理论键长、键角以及H和C核磁共振化学位移,验证了该理论水平的适用性。运用自然键轨道理论识别并量化分子内稳定相互作用,特别是供体原子与Ir(III)离子之间的相互作用。对配合物针对五种人类肿瘤细胞系进行了抗肿瘤活性测试:MCF-7乳腺腺癌、SW480结肠腺癌、518A2黑色素瘤、8505C人甲状腺癌和A253下颌下腺癌。配合物对顺铂耐药的MCF-7、SW480和8505C细胞系表现出优异的抗肿瘤活性。对8505C细胞的杀肿瘤作用机制表明半胱天冬酶诱导的细胞凋亡参与其中,同时伴随着处理细胞的ROS/RNS和增殖潜能的显著降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/ea2121972293/biomolecules-14-00420-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/71ddb50c01df/biomolecules-14-00420-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/81b12fa780a3/biomolecules-14-00420-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/4065ab61fd93/biomolecules-14-00420-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/13d8da808899/biomolecules-14-00420-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/673b629efe8d/biomolecules-14-00420-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/78be2f71d69d/biomolecules-14-00420-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/ea2121972293/biomolecules-14-00420-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/71ddb50c01df/biomolecules-14-00420-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/81b12fa780a3/biomolecules-14-00420-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/4065ab61fd93/biomolecules-14-00420-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/13d8da808899/biomolecules-14-00420-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/673b629efe8d/biomolecules-14-00420-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/78be2f71d69d/biomolecules-14-00420-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c36/11048224/ea2121972293/biomolecules-14-00420-g006.jpg

相似文献

1
(Pentamethylcyclopentadienyl)chloridoiridium(III) Complex Bearing Bidentate PhPCHCHSPh-κ,κ Ligand.带有双齿PhPCHCHSPh-κ,κ配体的(五甲基环戊二烯基)氯铱(III)配合物
Biomolecules. 2024 Mar 30;14(4):420. doi: 10.3390/biom14040420.
2
Anticancer potential of (pentamethylcyclopentadienyl)chloridoiridium(III) complexes bearing κP and κP,κS-coordinated Ph2 PCH2 CH2 CH2 S(O)x Ph (x=0-2) ligands.含有κP和κP,κS配位的Ph2PCH2CH2CH2S(O)xPh(x = 0 - 2)配体的(五甲基环戊二烯基)氯铱(III)配合物的抗癌潜力
ChemMedChem. 2014 Jul;9(7):1586-93. doi: 10.1002/cmdc.201300479. Epub 2014 Jan 27.
3
Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.中性和阳离子铱(III)配合物与 κP 和 κP,κS 配位的 Ph₂PCH₂S(O)xPh(x = 0-2)配体的生物活性。
Eur J Med Chem. 2013 Nov;69:216-22. doi: 10.1016/j.ejmech.2013.08.025. Epub 2013 Aug 29.
4
Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes.半夹心钌(II)和铱(III)配合物的生物活性
Anticancer Agents Med Chem. 2016;16(11):1455-1460. doi: 10.2174/1871520615666151029100749.
5
Arene Ruthenium(II) Complexes Bearing the κ- or κ-,κ- PhP(CH)SPh Ligand.芳基钌(II)配合物,具有 κ-或 κ-,κ- PhP(CH)SPh 配体。
Molecules. 2021 Mar 25;26(7):1860. doi: 10.3390/molecules26071860.
6
Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.含P^P螯合配体的半夹心铱(III)和钌(II)配合物:一类具有异常氧化还原特性的新型强效抗癌剂。
Inorg Chem. 2018 Feb 19;57(4):1705-1716. doi: 10.1021/acs.inorgchem.7b01959. Epub 2018 Feb 5.
7
Synthesis, molecular structure, computational study and in vitro anticancer activity of dinuclear thiolato-bridged pentamethylcyclopentadienyl Rh(III) and Ir(III) complexes.双核硫醇桥联茂金属铑(III)和铱(III)配合物的合成、分子结构、计算研究及体外抗癌活性。
Dalton Trans. 2013 Nov 21;42(43):15457-63. doi: 10.1039/c3dt51991k.
8
A Comparative Analysis of the In Vitro Anticancer Activity of Iridium(III) {η-CMeR} Complexes with Variable R Groups.具有可变R基团的铱(III) {η-CMeR}配合物的体外抗癌活性比较分析
Int J Mol Sci. 2021 Jul 10;22(14):7422. doi: 10.3390/ijms22147422.
9
Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.新型多功能亚胺-N-杂环卡宾半夹心型铱(III)配合物作为溶酶体靶向抗癌剂。
Inorg Chem. 2018 Sep 4;57(17):11087-11098. doi: 10.1021/acs.inorgchem.8b01656. Epub 2018 Aug 22.
10
Activation of the Ir-N(pyridine) Bond in Half-Sandwich Tethered Iridium(III) Complexes.半夹心型 tethered 铱(III)配合物中 Ir-N(pyridine)键的活化。
Inorg Chem. 2020 Nov 16;59(22):16454-16466. doi: 10.1021/acs.inorgchem.0c02287. Epub 2020 Oct 26.

引用本文的文献

1
Cytotoxic Organometallic Iridium(III) Complexes.细胞毒性有机金属铱(III)配合物
Molecules. 2025 Feb 9;30(4):801. doi: 10.3390/molecules30040801.

本文引用的文献

1
Research Progress of Metal Anticancer Drugs.金属抗癌药物的研究进展
Pharmaceutics. 2023 Dec 11;15(12):2750. doi: 10.3390/pharmaceutics15122750.
2
Exploring the Potential of Metal-Based Candidate Drugs as Modulators of the Cytoskeleton.探索基于金属的候选药物作为细胞骨架调节剂的潜力。
Chembiochem. 2023 Sep 1;24(17):e202300178. doi: 10.1002/cbic.202300178. Epub 2023 Aug 1.
3
Triphenyltin(IV) Carboxylates with Exceptionally High Cytotoxicity against Different Breast Cancer Cell Lines.三苯基锡(IV)羧酸酯对不同乳腺癌细胞系具有极高的细胞毒性。
Biomolecules. 2023 Mar 26;13(4):595. doi: 10.3390/biom13040595.
4
Special Issue "Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0".特刊征稿:癌症治疗中的顺铂:作用机制 3.0
Int J Mol Sci. 2023 Apr 27;24(9):7917. doi: 10.3390/ijms24097917.
5
The Challenging Treatment of Cisplatin-Resistant Tumors: State of the Art and Future Perspectives.顺铂耐药肿瘤的挑战性治疗:现状与未来展望。
Molecules. 2023 Apr 12;28(8):3407. doi: 10.3390/molecules28083407.
6
Cisplatin in Ovarian Cancer Treatment-Known Limitations in Therapy Force New Solutions.顺铂在卵巢癌治疗中的应用——已知的治疗局限性促使新的解决方案出现。
Int J Mol Sci. 2023 Apr 20;24(8):7585. doi: 10.3390/ijms24087585.
7
Cytotoxicity and mechanism of action of metal complexes: An overview.金属配合物的细胞毒性和作用机制:概述。
Toxicology. 2023 Jun 15;492:153516. doi: 10.1016/j.tox.2023.153516. Epub 2023 Apr 20.
8
Tumour microenvironment and aberrant signaling pathways in cisplatin resistance and strategies to overcome in oral cancer.口腔癌中顺铂耐药的肿瘤微环境和异常信号通路及克服策略。
Arch Oral Biol. 2023 Jul;151:105697. doi: 10.1016/j.archoralbio.2023.105697. Epub 2023 Apr 13.
9
Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses.金属有机抗肿瘤剂:从生物分子到动态生物过程的靶向治疗。
Chem Soc Rev. 2023 Apr 24;52(8):2790-2832. doi: 10.1039/d2cs00757f.
10
Recent Trends in the Development of Novel Metal-Based Antineoplastic Drugs.新型金属抗肿瘤药物的研究进展。
Molecules. 2023 Feb 18;28(4):1959. doi: 10.3390/molecules28041959.